^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LAE001

    i
    Other names: LAE001, CFG920, CFG-920, LAE 001, LAE-001, CFG 920
    Associations

    News

    Trials
    Company:
    Laekna Therap, Novartis
    Drug class:
    CYP17A1 inhibitor, Aldosterone synthase inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov)
    P1/2, N=49, Completed, Laekna Limited | Active, not recruiting --> Completed | N=74 --> 49 | Trial completion date: Oct 2024 --> Mar 2024
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • BRCA (Breast cancer early onset)
    |
    docetaxel • prednisone • afuresertib (LAE002) • LAE001
    10ms
    A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer (clinicaltrials.gov)
    P1/2, N=33, Suspended, Laekna Limited | N=80 --> 33 | Trial completion date: Aug 2022 --> Jun 2025 | Unknown status --> Suspended | Trial primary completion date: Feb 2022 --> Oct 2023
    Enrollment change • Trial completion date • Trial suspension • Trial primary completion date
    |
    LAE001
    almost2years
    Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, Laekna Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    docetaxel • afuresertib (LAE002) • LAE001
    2years
    Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov)
    P1/2, N=74, Recruiting, Laekna Limited | Trial completion date: Oct 2022 --> Oct 2024 | Trial primary completion date: Sep 2022 --> Oct 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    docetaxel • afuresertib (LAE002) • LAE001
    3years
    Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov)
    P1/2, N=74, Recruiting, Laekna Limited | Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    docetaxel • afuresertib (LAE002) • LAE001